1. Rationale for Early Intervention: The Importance of Neutralizing Antibodies in the Management of Patients on Beta interferon. Presented during the Workshop Current Controversies in the Treatment of Multiple Sclerosis held during the 1997 annual meeting of the Consortium of Multiple Sclerosis Centers, in Calgary, Alberta, Canada.
   Request an Audio Tape of Dr. Vartanian's Presentation
2. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. "Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years." Neurology 1996; 47:889-894.
3. Paty DW, Goodkin D, Thompson A, et al. Guidelines for physicians with patients on IFN-beta-1b: the use of an assay for neutralizing antibodies (NAB). Neurology 1996; 47:865-866.
4. Rudick et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis, Neurology; 1998, 50:1266-1272.
5. "Neutralizing the Opposition", in Neuro News: Clinical Highlights of the American Academy of Neurology’s 49th Annual Meeting, Boston, MA. 2,2;1997:8-12.
6. Rudick, R. et al. Disease Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics. Archives of Neurology 1999; 56:1079-1084.
7. Deisenhammer, MD, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
8. Kastrukoff LF, et al., Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon b-1B. Neurology 1999 Jan 15;52:351-9

Additional References

1. Antonelli G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiviral Res 1994; 24:235-244.
2. Antonelli G, Currenti M, Turriziani O, et al. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163:882-885.
3. Antonelli G, Dianzani F. Anti-interferon antibodies. Haematologica 1991; 76(Suppl 4): 50.
4. Antonelli G, Giannelli G, Pistello M, et al. Clinical significance of recombinant interferon-alpha 2 neutralizing antibodies in hepatitis patients. J Interferon Res 1994; 14:211-213.
5. Bonetti P, Diodati G, Drago C, et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol 1994; 20:416-420.
6. Brand CM, Leadbeater L, Bellati G, et al. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J Interferon Res 1993; 13:121-125.
7. Brand CM, Leadbeater L, Budiman R, et al. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies. Br J Haematol 1994; 86:216-218.
8. Casato M, Antonelli G, Maggi F, et al. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. J Biol Regul Homeost Agents 1994; 8:56-59.
9. Dummer R, Muller W, Nestle F, et al. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 1991; 67:2300-2304.
10. Fiehn C, Prummer O, Gallati H, et al. Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies. Eur J Clin Invest 1995; 25:615-618.
11. Fierlbeck G, Schreiner T. Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-beta. J Interferon Res 1994; 14:205-206.
12. Fierlbeck G, Schreiner T, Schaber B, et al. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother 1994; 39:263-268.
13. Freund M, von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989; 72:350-356.
14. Giannelli G, Antonelli G, Fera G, et al. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 1994; 97:4-9.
15. Hansen MB, Ross C, Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Methods 1990; 127:241-248.
16. Havell EA. Production and quantitation of neutralizing antibodies for human fibroblasts interferon. Methods Enzymol 1981; 79(Pt B):571-575.
17. Human antibodies to interferons: report of a National Institutes of Health Workshop held 25-26 July 1988 in Bethesda, MD. J Interferon Res 1988; 8:v-vii.
18. Itri LM, Sherman MI, Palleroni AV, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. J Interferon Res 1989; 9(Suppl 1):S9-S15.
19. Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12:1266-1270.
20. Milella M, Antonelli G, Santantonio T, et al. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13:146-150.
21. Oberg K, Alm GV. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J Interferon Res 1989; 9(Suppl 1): S45-S49.
22. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81:531-535.
23. Prummer, O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. Cancer 1993; 71:1828-1834.
24. Redlich PN, Grossberg SE. Analysis of antigenic domains on natural and recombinant human IFN-beta by the inhibition of biologic activities with monoclonal antibodies. J Immunol 1989; 143:1887-1893.
25. Redlich PN, Hoeprich PD, Colby CB, et al. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 1991; 88:4040-4044.
26. Roffi L, Mels GC, Antonelli G, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995; 21:645-649.
27. Ronnblom LE, Janson ET, Perers A, et al. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 1992; 89:330-335.
28. Russo D, Candoni A, Zuffa E, et al. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. Br J Haematol 1996; 94:300-305.
29. Steis RG, Smith JW 2d, Urba WJ, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318:1409-1413.
30. Thurmond LM, Brand CM, Leventhal BG, et al. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon. J Lab Clin Med 1991; 118:232-240.